top of page
EMPRESS
GIREDESTRANT (GDC-9545) OR TAMOXIFEN IN ER+/HER2- Ki67≥10% EARLY BREAST CANCER
THE PRIMARY OBJECTIVE IS TO ASSESS CHANGES IN TUMOR CELL PROLIFERATION AS MEASURED BY KI67 EXPRESSION BETWEEN BASELINE AND POST-TREATMENT TUMOR BIOPSY SAMPLES BY CENTRAL ASSESSMENT IN PATIENTS WITH CENTRALLY CONFIRMED KI67>10% IN GIREDESTRANT VS. TAMOXIFEN. IN ADDITION, THE STUDY WILL MEASURE COMPLETE CELL CYCLE ARREST, ANALYZE CHANGES IN ER AND PGR LEVELS, COMPLETE MOLECULAR PROFILING USING HTG, AND EVALUATE TOXICITY.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
ER+/HER2- Ki67≥10% Early Breast Cancer
20
92
II
Spain, France
Closing
CLINICAL TRIAL DETAILS
PRESS RELEASE
SCIENTIFIC IMPACT
ESMO 2025 presentation: https://www.medsir.org/_files/ugd/39f166_66659190c0d1424ea661b4ec21e15293.pdf | ESMO 2025 lay language summary: https://www.medsir.org/_files/ugd/39f166_bc0a292364f34de69651e706605955ba.pdf
BLOG ARTICLES RELATED
TRIAL SITES
Instituto Valenciano de Ocología (Spain) | Hospital Clínic i Provincial de Barcelona (Spain) | Hospital Clínico Universitario de Valencia (Spain) | Hospital Arnau de Vilanova de Valencia (Spain) | Hospital General Universitario Dr. Balmis (Spain) | Hospital Universitari Dexeus (Spain) | Hospital Universitari San Joan de Reus (Spain) | Hospital Universitario de Navarra (CUN) (Spain) | Hospital Universitario de Basurto (Spain) | Institut Català d’ Oncologia Badalona (Spain) | Hospital Ruber Internacional (Spain) | Hospital Universitario Ramón y Cajal (Spain) | Hospital Universitario de León (Spain) | Hospital Europeen Georges Pompidou (France) | Hôpital Tenon AP-HP (France)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page